MRNA vs. BIIB, ARGX, BNTX, NBIX, TECH, RGEN, QGEN, CRSP, DNLI, and TBIO
Should you be buying Moderna stock or one of its competitors? The main competitors of Moderna include Biogen (BIIB), argenx (ARGX), BioNTech (BNTX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Repligen (RGEN), Qiagen (QGEN), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), and Telesis Bio (TBIO). These companies are all part of the "medical" sector.
Moderna (NASDAQ:MRNA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
75.3% of Moderna shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 15.7% of Moderna shares are owned by company insiders. Comparatively, 0.6% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Biogen received 1575 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 72.02% of users gave Biogen an outperform vote while only 58.31% of users gave Moderna an outperform vote.
In the previous week, Moderna had 20 more articles in the media than Biogen. MarketBeat recorded 35 mentions for Moderna and 15 mentions for Biogen. Moderna's average media sentiment score of 0.47 beat Biogen's score of 0.32 indicating that Moderna is being referred to more favorably in the media.
Moderna has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Biogen has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.
Moderna currently has a consensus price target of $129.82, indicating a potential upside of 20.85%. Biogen has a consensus price target of $305.68, indicating a potential upside of 42.05%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.
Biogen has a net margin of 11.81% compared to Moderna's net margin of -68.84%. Biogen's return on equity of 14.91% beat Moderna's return on equity.
Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Summary
Biogen beats Moderna on 13 of the 18 factors compared between the two stocks.
Get Moderna News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools